Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Everolimus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    314 result(s) found for: Everolimus. Displaying page 13 of 16.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next»
    EudraCT Number: 2010-019966-95 Sponsor Protocol Number: CRAD001L2402T Start Date*: 2011-01-13
    Sponsor Name:Duke University
    Full Title: A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
    Medical condition: Histologically confirmed advanced Renal Cell Carcinoma, with non-clear cell pathology.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016640-39 Sponsor Protocol Number: PCLD003 Start Date*: 2010-05-31
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers.
    Medical condition: Isolated polycystic liver disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048834 Polycystic liver disease LLT
    12.1 10048834 Polycystic liver disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003194-10 Sponsor Protocol Number: 789456 Start Date*: 2019-03-19
    Sponsor Name:UMCG
    Full Title: OPen label multicenter randomized Trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de no...
    Medical condition: de novo renal transplantation in elderly patients.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004557-14 Sponsor Protocol Number: NA Start Date*: 2015-02-09
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King’s College Hospital NHS Foundation Trust
    Full Title: Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation
    Medical condition: Immunosuppression withdrawal in liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004432-38 Sponsor Protocol Number: CINC424D2301 Start Date*: 2017-10-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogeneic stem cel...
    Medical condition: corticosteroid refractory chronic Graft vs Host Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10072158 Chronic graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10072159 Chronic graft versus host disease in skin PT
    20.1 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    20.1 10021428 - Immune system disorders 10072160 Chronic graft versus host disease in liver PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) AT (Completed) ES (Ongoing) BE (Completed) DK (Completed) NL (Completed) IT (Completed) FR (Completed) PT (Completed) HU (Completed) PL (Completed) BG (Completed) NO (Completed) GR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-002867-41 Sponsor Protocol Number: OPS-C-001/D-FR-01072-001 Start Date*: 2015-12-10
    Sponsor Name:Ipsen Pharma
    Full Title: An international multi-center, open-label study to evaluate safety, tolerability, biodistribution, dosimetry and preliminary efficacy of 177Lu-OPS201 for the therapy of somatostatin receptor positi...
    Medical condition: Neuroendocrine tumors (NETs)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (GB - no longer in EU/EEA) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005294-60 Sponsor Protocol Number: CRAD001C24114 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Multicenter, triple-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tis...
    Medical condition: histological evidence of progressive or metastatic bone or soft tissue sarcomas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039494 Sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000077-38 Sponsor Protocol Number: CRAD001L2201 Start Date*: 2008-10-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cel...
    Medical condition: Patients with metastatic clear cell carcinoma of the kidney
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) DE (Completed) IT (Prematurely Ended) FR (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010640-34 Sponsor Protocol Number: THYTOTRA Start Date*: 2009-08-13
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: INDUCTION OF DONOR-SPECIFIC TOLERANCE IN PATIENTS WITH LIVER TRANSPLANTATION WITH RECIPIENT PRE-TREATMENT WITH THYMOGLOBULINE AND MINIMAL POST-TRANSPLANT IMMUNOSUPPRESSION.
    Medical condition: Adult recipients of first liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024715 Liver transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000473-23 Sponsor Protocol Number: RETRY Start Date*: 2012-05-29
    Sponsor Name:GIOM - Gruppo Italiano Oncologia Nefrologica
    Full Title: PHASE II STUDY OF SUNITINIB AS RECHALLENGE THIRD-LINE THERAPY IN METASTATIC RENAL CANCER
    Medical condition: Metastatic renal cancer thrid-line therapy already treated in fist-line therapy with Sunitinib.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009251 Clear cell carcinoma of the kidney LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000819-25 Sponsor Protocol Number: 43712 Start Date*: 2013-10-22
    Sponsor Name:Leiden University Medical Center
    Full Title: Autologous BM derived MSCs in combination with everolimus to preserve renal structure and function in renal recipients
    Medical condition: renal recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006841-25 Sponsor Protocol Number: CRAD001CCH08t Start Date*: 2009-08-24
    Sponsor Name:Oncology Institute of Southern Switzerland
    Full Title: Phase II study of the combination of RAD001 and Letrozole in patients with recurrent endometrial cancer
    Medical condition: Recurrent endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014742 Endometrial neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003604-21 Sponsor Protocol Number: KT-IBA Start Date*: 2011-10-24
    Sponsor Name:Universitätsklinik für Innere Medizin IV, Medizinische Universität Innsbruck
    Full Title: The role of immunosuppressives in immunosenescence and immunotolerance in renal transplantation
    Medical condition: The impact of immunosuppressives on age-related changes of the immune system will be analyzed in patients after renal transplantation. Only patients at least one year after renal tranplantation and...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10062016 Immunosuppression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004539-22 Sponsor Protocol Number: 11-2012 Start Date*: 2013-03-18
    Sponsor Name:I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY
    Full Title: An open label, single arm, phase II study to evaluate the activity and toxicity of Panitumumab in pre-treated patients with advanced well differentiated neuroendocrine tumor (G1 and G2)
    Medical condition: Well differentiated neuroendocrine tumor (G1 and G2)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000823-11 Sponsor Protocol Number: TIMO Start Date*: 2023-03-09
    Sponsor Name:Sahlgrenska University Hospital Gothenburg
    Full Title: Ticagrelor monotherapy after coronary stenting in patients with acute myocardial infarction. A prospective single-centre, single-arm phase II study
    Medical condition: Antiplatelet therapy in patients who undergo coronary artery stenting due to coronary artery disease (CAD) or acute coronary syndrome (ACS). The present study will examine whether ticagrelor, as mo...
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004849 10048560 Coronary artery disease aggravated LLT
    20.0 100000004849 10071111 Non ST segment elevation acute coronary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001207-68 Sponsor Protocol Number: KKSH140 Start Date*: 2018-11-20
    Sponsor Name:Martin-Luther-Universität Halle-Wittenberg
    Full Title: A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors
    Medical condition: Progressive well-differentiated metastatic pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    21.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-021755-34 Sponsor Protocol Number: 2010-021755-34 Start Date*: 2010-07-22
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study on imatinib in combination with RAD001 in advanced chordoma
    Medical condition: PDGFRB and mTOR (or S6 or 4BP1) positive advanced chordoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039492 LLT
    9.1 10006007 PT
    9.1 10039498 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002190-21 Sponsor Protocol Number: MAR-BAS-18-005 Start Date*: 2020-07-08
    Sponsor Name:Fondazione per la Medicina Personalizzata
    Full Title: The ROME trial from histology to target: the road to personalize target therapy and immunotherapy
    Medical condition: Patients with progressive disease (recurrent and/or metastatic) of breast cancer, metastatic gastro-intestinal tumors, non small cell lung cancer (NSCLC) or others. Patients should have completed a...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066275 Comedocarcinoma of breast LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007351 Carcinoma gastrointestinal LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071533 Lung squamous cell carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003018-41 Sponsor Protocol Number: CRAD001C2235 Start Date*: 2005-08-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Open label, non-randomized, phase 2 Study investigating the effect of RAD001 monotherapy in patients with advanced NSCLC previously treated with either chemotherapy only or with chemotherapy and EG...
    Medical condition: Lung cancer is one of the most common malignancies in developed countries and accounts for millions of deaths worldwide. In 2000, the annual incidence of non-small cell lung cancer (NSCLC), which c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005616-14 Sponsor Protocol Number: M13-596 Start Date*: 2016-05-31
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients with Chronic Hepatitis C Virus Genotype 1 ...
    Medical condition: Hepatitis C Virus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 14:16:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA